Kolon Life Science Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was KRW 33.97 million compared to KRW 25.24 million a year ago. Net loss was KRW 7,015.15 million compared to net income of KRW 464.16 million a year ago. Basic loss per share from continuing operations was KRW 615 compared to basic earnings per share from continuing operations of KRW 78 a year ago. Diluted loss per share from continuing operations was KRW 615 compared to diluted earnings per share from continuing operations of KRW 78 a year ago. Basic loss per share was KRW 615 compared to basic earnings per share of KRW 41 a year ago.
For the nine months, sales was KRW 111.15 million compared to KRW 79.76 million a year ago. Net loss was KRW 17,310.4 million compared to net income of KRW 2,648.09 million a year ago. Basic loss per share from continuing operations was KRW 1,773 compared to basic earnings per share from continuing operations of KRW 311 a year ago. Diluted loss per share from continuing operations was KRW 1,773 compared to diluted earnings per share from continuing operations of KRW 311 a year ago. Basic loss per share was KRW 1,517 compared to basic earnings per share of KRW 232 a year ago.